<DOC>
	<DOCNO>NCT01941693</DOCNO>
	<brief_summary>There high rate psychological comorbidity people suffer alcohol dependence . There need effective integrated treatment alcohol dependence comorbid anxiety depression . This study test efficacy novel integrate intervention comorbid alcohol dependence anxiety mood disorder .</brief_summary>
	<brief_title>A Randomized Controlled Trial Structured Stepped-care Intervention Psychiatric Comorbidity</brief_title>
	<detailed_description>In summary , specific aim project : 1 . To assess effectiveness novel step care intervention alcohol dependent patient co-morbid anxiety and/or depression compare usual treatment alcohol dependence promote abstinence alcohol increase quality life reduce symptom anxiety depression . 2 . To describe important factor relate maintenance alcohol-related psychiatric comorbidity . Step 1 : All subject complete 12 week pharmacotherapy ( n = 120 ) naltexone ( 50 mg , 1 tablet daily ) , acamprosate ( 333 mg , 2 tablet 3 time daily , reduce 4/day woman &lt; 65kg ) , combination two . After 3 week stabilization period , subject undergo complete formal assessment anxiety depression . Those subject diagnosis anxiety depressive disorder regardless drink outcome offer next step care follow 12-16 week . Step 2 : Subjects undergo next step care ( n = 30 per group , 60 total ) randomize refer consecutively assign subject identification number match numbered envelope contain random assignment card . Randomization stratify accord concomitant SSRI use . The treatment group : 1 . Intervention comorbid anxiety depression , 2 . Usual counseling care .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Inclusion Criteria Step 1 : alcohol dependence accord DSMIV criterion , alcohol subject 's drug choice , age 1865 , adequate cognition English language skill give valid consent complete research interview ( assess mini mental state examination ) , willingness give write consent , abstinence alcohol 3 21 day ( standard clinical criterion use acamprosate naltrexone ) , resolution clinically evident alcohol withdrawal ( score 01 RPA hospital alcohol withdrawal scale ) , positive score initial comorbidity suspicion checklist ( CSC ) . Exclusion Criteria Step 1 : sensitivity study medication therapy drug within 6 month , active major psychiatric disorder associate significant suicide risk , pregnancy lactation , advance liver disease ( hepatocellular failure , variceal bleeding , ascites encephalopathy ) , serious medical illness would interfere adherence study protocol . Entry criterion step 2 : Completion 3 week acamprosate and/or natlrexone and/or , resolution clinically evident alcohol withdrawal ( score 01 RPA hospital alcohol withdrawal scale ) , case formulation diagnosis anxiety depression ( see ) . Exclusion criteria 2 : Noncompliance acamprosate and/or naltrexone , alcohol consumption baseline level , resolution clinically evident anxiety depression assess case formulation ( see ) . These patient offer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>alcohol</keyword>
	<keyword>anxiety</keyword>
	<keyword>depression</keyword>
	<keyword>comorbidity</keyword>
	<keyword>CBT</keyword>
</DOC>